congress
December 1, 2016 Uncategorized No Comments

Cardiocity’s RhythmPad has completed another NIHR accredited clinical trial and provided an accuracy of 97% with regards comparison blinded analysis of a Gold Standard 12 lead with the RhythmPad’s 6 lead output. The trial, conducted on 752 patients, which was undertaken at St Peter’s Hospital in Chertsey, Surrey, UK concluded a sensitivity and specificity of 93% and 98% respectively.

Cardiocity’s Dr Chris Crockford said of the trial “Cardiocity’s RhythmPad remains the only clinically validated 1 and 6 lead Mass Screening device for Cardiac Arrhythmia. Hand held devices will never work on the 5% of people who are isoelectric when measured from the hands. Cardiocity’s RhythmPad was designed to enable screening of 100% of the population and as such we have now verified the performance of the system.”

An abstract was published at the 17th International Symposium on Progress in Clinical Pacing 2016, www.pacing2016.com

 

 

 

Written by Chris Crockford